KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased Short-Term Debt issuances

West Pharmaceutical Services (WST) Long-Term Debt Repayments (2016 - 2024)

West Pharmaceutical Services has reported Long-Term Debt Repayments over the past 12 years, most recently at $132.9 million for Q3 2024.

Quarterly Long-Term Debt Repayments changed N/A to $132.9 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $132.9 million through Jun 2025, up 268.14% year-over-year, with the annual reading at $169.0 million for FY2024, 7247.83% up from the prior year.
Long-Term Debt Repayments was $132.9 million for Q3 2024 at West Pharmaceutical Services, up from $35.5 million in the prior quarter.
Over five years, Long-Term Debt Repayments peaked at $132.9 million in Q3 2024 and troughed at -$600000.0 in Q2 2020.